Twenty years after Japanese scientists first reprogrammed mature cells back into an embryonic-like state, Japan has crossed a threshold no other nation has reached. The country's health ministry has endorsed issuing conditional approval for two first-of-a-kind medicines. This milestone marks the first time such treatments will be put to practical, commercial use globally.
The two therapies target some of medicine's most intractable problems. Amchepry, made by Sumitomo Pharma and Racthera, both in Tokyo, for the treatment of Parkinson's disease, has been tested in seven people. ReHeart, made by Cuorips in Tokyo for severe heart failure, has been tested in eight people. By conventional drug-approval standards, this is extraordinarily thin evidence. Yet both now have the green light to enter the market.
The mechanism behind these therapies rests on a deceptively simple insight. In 2006, Shinya Yamanaka and Kazutoshi Takahashi at Kyoto University unveiled a simple recipe for reprogramming mature cells into induced pluripotent stem (iPS) cells, providing a new source of cells that can be transformed into other cell types. Yamanaka shared a 2012 Nobel prize for his role in the work. For Parkinson's patients, the treatment involves collecting blood cells from volunteers, reprogramming them into iPS cells and then coaxing the reprogrammed cells into becoming dopamine-making progenitor cells, which neurosurgeons then test by transplanting into the brains of people with Parkinson's disease.
How small are the clinical datasets supporting these approvals? In the Parkinson's study, each of seven patients received a total of either five million or 10 million cells implanted on both sides of the brain. Four patients showed improvements in symptoms. No major adverse effects were found over a two-year follow-up. This is promising. But it is not what regulatory agencies in the United States, Europe, or Australia typically require before releasing a therapy to the general population.
Japan's approach differs fundamentally. The country introduced policies designed to accelerate the development of regenerative medicine, allowing certain therapies to receive conditional approval earlier than they might in other countries, with promising treatments approved after early clinical studies if they demonstrate safety and potential effectiveness. The companies can then sell their drugs for seven years to a limited number of people, during which time they will continue to track how people respond to better assess safety and efficacy.
The regulatory logic is not unreasonable. For patients with Parkinson's or advanced heart failure, existing treatments are palliative rather than curative. Current treatments primarily focus on managing symptoms rather than stopping the disease itself, with medications such as dopamine-replacement drugs reducing tremors and stiffness but typically becoming less effective over time. A therapy with even preliminary evidence of benefit could represent a meaningful advance.
But the accelerated pathway carries real risks, and not all stem-cell experts are convinced Japan has struck the right balance. Paul Knoepfler, a stem-cell researcher at the University of California, Davis, calls the arrangement "a risky regulatory experiment," noting that bigger trials are needed to ensure that the drugs are safe and effective. Critics said the streamlined approval process could overlook risks, including concerns that implanted stem cells might form tumours called teratomas.
The international stem-cell research community is watching closely. As of 2026, no iPSC-based therapy has completed a full three-phase clinical trial and received FDA approval. In 2020, a group at the University of Sydney launched what is apparently the first phase 3 trial of iPS cells, an effort to treat osteoarthritis of the knee. This suggests that the rest of the world is proceeding with greater caution.
Reassuringly, as of December 2024, 1,200 patients have received human pluripotent stem cell products in the course of clinical trials, so far showing no generalizable safety concerns. This broader evidence base provides some comfort that iPS cell therapies, when properly manufactured and deployed, may be safer than early sceptics feared. Yet 1,200 patients across dozens of trials globally is far smaller than the typical Phase 3 database for a new drug in mature markets.
Japan's decision reflects a calculated gamble: that the potential benefit of rapid access for desperate patients outweighs the regulatory risks of limited prior evidence. Shinya Yamanaka, director emeritus at Kyoto University's Centre for iPS Cell Research and Application, stated: "I am very happy to see the first big step towards its societal implementation, 20 years since it was announced." The therapies could be available to patients under Japanese insurance coverage as early as this summer.
The real test will come over the next seven years. If Amchepry and ReHeart prove effective and safe in larger patient populations, Japan will have demonstrated a model for translating basic science into clinical benefit faster than conventional regulatory pathways allow. If safety signals emerge or efficacy fails to materialise, the regulatory decision will be remembered as a cautionary tale about moving too quickly. For now, Japanese patients with these conditions face a choice: enter a post-market surveillance study for an unproven therapy, or continue with existing treatments they may have already exhausted. For many, that choice will not feel like a difficult one.